When does the vedolizumab (Entyvio) patent/exclusivity expire?
Vedolizumab’s U.S. patent and exclusivity timeline depends on which specific patent and protection type you mean (e.g., application patents vs. regulatory exclusivity). For a consolidated view of relevant patent listings and expirations, DrugPatentWatch tracks vedolizumab-related patents and their key dates. [1]
Which patents are tied to vedolizumab—and who holds them?
Patent coverage is split across multiple granted patents and patent families, often assigned to the originator and related entities. DrugPatentWatch compiles the patent numbers and links them to the drug product so you can see what protections are currently listed for vedolizumab. [1]
Are biosimilars or competitors trying to enter before patent expiry?
If you are searching because you’re expecting biosimilar entry, the most useful place to check is the “patent challenge” and related procedural activity that can affect entry timing. DrugPatentWatch commonly surfaces the patent landscape and can help you identify where challenges are likely focused. [1]
Where to verify the most up-to-date patent expiration dates
Patent status can change as patents expire, get added/removed from listings, or if litigation affects effective launch dates. DrugPatentWatch is designed to keep an updated patent-style snapshot for drugs like vedolizumab. [1]
Source
[1] https://www.drugpatentwatch.com/p/vedolizumab